Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) shares traded up 7.2% on Wednesday . The company traded as high as $14.39 and last traded at $14.46. 377,074 shares traded hands during mid-day trading, a decline of 52% from the average session volume of 787,141 shares. The stock had previously closed at $13.48.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on the stock. HC Wainwright restated a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research note on Thursday, January 2nd. Cantor Fitzgerald raised their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an "overweight" rating in a report on Thursday, November 14th. Finally, Piper Sandler started coverage on shares of Capricor Therapeutics in a report on Monday, October 21st. They issued an "overweight" rating and a $35.00 price objective for the company. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. According to MarketBeat, Capricor Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $34.50.
Read Our Latest Research Report on Capricor Therapeutics
Capricor Therapeutics Stock Performance
The stock's 50 day simple moving average is $14.15 and its 200 day simple moving average is $13.01. The firm has a market cap of $725.25 million, a P/E ratio of -15.05 and a beta of 4.08.
Hedge Funds Weigh In On Capricor Therapeutics
Institutional investors have recently modified their holdings of the business. Magnus Financial Group LLC purchased a new position in shares of Capricor Therapeutics in the 4th quarter worth about $276,000. State Street Corp boosted its stake in Capricor Therapeutics by 27.8% in the third quarter. State Street Corp now owns 512,313 shares of the biotechnology company's stock valued at $7,792,000 after acquiring an additional 111,291 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Capricor Therapeutics by 419.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 56,199 shares of the biotechnology company's stock valued at $855,000 after acquiring an additional 45,381 shares during the period. Point72 Asset Management L.P. purchased a new stake in shares of Capricor Therapeutics during the 3rd quarter worth approximately $3,806,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Capricor Therapeutics in the 3rd quarter worth approximately $161,000. 21.68% of the stock is owned by institutional investors.
Capricor Therapeutics Company Profile
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
See Also
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
